Compare BIO-TECHNE Corp (TECH) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs VICI Properties Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while VICI Properties Inc trades at $26.02 (market cap $28.71B). The key difference: VICI Properties Inc is far larger — about 2.6× BIO-TECHNE Corp's market cap, and VICI Properties Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| TECH | VICI | |
|---|---|---|
Market Cap | $11.24B | $28.71B |
Sector | Health | Real Estate |
52-Week High | $72.29 | $33.78 |
52-Week Low | $43.31 | $25.94 |
Enterprise Value | $11.32B | $46.26B |
Dividend Yield | 0.44% | 6.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VICI Properties trades at $26.74, up 0.66% today, with a neutral technical signal and strong fundamentals including a 67.5% net income margin and a P/E of 10.1. Recent Q2 2026 earnings showed an EPS miss but revenue beat, while the company raised its full-year AFFO guidance. A $1.75 billion note offering in August 2026 supports capital deployment.
The outlook remains positive with a 76.9% analyst buy rating and a $29.83 consensus price target, offering potential upside. Risks include earnings volatility and high debt, but the near 7% dividend yield and stable cash flows provide investor appeal in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
